SY-5007

SY-5007 · Shouyao Holdings (Beijing) Co. LTD

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SY-5007, covering 2023-04-12 to 2026-06-16. Get the full timeline:

Most recent: Clinical Trial Update: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC [Phase 3]

See pricing